EMPA-REG OUTCOME: The Cardiologist's Point of View

被引：16

作者：

Pham, Son V. ^{[1
]}

Chilton, Robert J. ^{[1
]}

机构：

[1] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2017年 / 120卷 / 01期

关键词：

COTRANSPORTER; 2; INHIBITORS; TYPE-2; DIABETES-MELLITUS; HEART-RATE-VARIABILITY; CORONARY FLOW RESERVE; ARTERIAL STIFFNESS; BLOOD-PRESSURE; CARDIOVASCULAR OUTCOMES; VASCULAR-RESISTANCE; EMPAGLIFLOZIN; DISEASE;

D O I：

10.1016/j.amjcard.2017.05.011

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cardiologists could view empagliflozin as a cardiovascular drug that also has a beneficial effect on reducing hyperglycemia in patients with type 2 diabetes mellitus (T2DM). The effects of empagliflozin in lowering the risk of cardiovascular death and hospitalization for heart failure in T2DM patients with high cardiovascular risk during the recent Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) trial may be explained principally in terms of changes to cardiovascular physiology; namely, by the potential ability of empagliflozin to reduce cardiac workload and myocardial oxygen consumption by lowering blood pressure, improving aortic compliance, and improving ventricular arterial coupling. These concepts and hypotheses are discussed in this report. (C) 2017 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

引用

页码：S53 / S58

页数：6

共 50 条

[31] The interim experts' council resolution on the EMPA-REG OUTCOME trial issues [J].

Shestakova, M. V. ;

Boytsov, S. A. ;

Drapkina, O. M. ;

Demidova, T. Yu. ;

Drexel, H. ;

Antsiferov, M. B. ;

Petunina, N. A. ;

Chernikova, I. A. ;

Kalashnikov, V. Yu. ;

Bardymova, T. P. ;

Protasov, V. K. ;

Babenko, A. Yu. ;

Ruyatkina, L. A. ;

Klimontov, V. V. ;

Salukhov, V. V. ;

Fadeev, V. V. ;

Karpov, Yu. A. .

RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2016, 12 (02) :186-190

[32] Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial [J].

Inzucchi, Silvio E. ;

Wanner, Christoph ;

Hehnke, Uwe ;

Zwiener, Isabella ;

Kaspers, Stefan ;

Clark, Douglas ;

George, Jyothis T. ;

Zinman, Bernard .

DIABETES CARE, 2019, 42 (04) :E53-E55

[33] Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome Analysis of EMPA-REG OUTCOME using REDUCE-IT criteria [J].

Verma, Subodh ;

Kosmopoulos, Andrew ;

Bhatt, Deepak L. ;

Fitchett, David ;

Ofstad, Anne Pernille ;

Wanner, Christoph ;

Mattheus, Michaela ;

Zinman, Bernard ;

Lawler, Patrick R. ;

Leiter, Lawrence A. .

AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023, 15

[34] Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial [J].

Monteiro, Pedro ;

Bergenstal, Richard M. ;

Toural, Elvira ;

Inzucchi, Silvio ;

Zinman, Bernard ;

Hantel, Stefan ;

Kis, Sanja Giljanovic ;

Kaspers, Stefan ;

George, Jyothis T. ;

Fitchett, David .

AGE AND AGEING, 2019, 48 (06) :859-866

[35] The EMPA-REG outcome study: critical appraisal and potential clinical implications [J].

Gianluca Perseghin ;

Anna Solini .

Cardiovascular Diabetology, 15

[36] How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial [J].

Inzucchi, Silvio E. ;

Zinman, Bernard ;

Fitchett, David ;

Wanner, Christoph ;

Ferrannini, Ele ;

Schumacher, Martin ;

Schmoor, Claudia ;

Ohneberg, Kristin ;

Johansen, Odd Erik ;

George, Jyothis T. ;

Hantel, Stefan ;

Bluhmki, Erich ;

Lachin, John M. .

DIABETES CARE, 2018, 41 (02) :356-363

[37] Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial [J].

Ferreira, Joao Pedro ;

Inzucchi, Silvio E. ;

Mattheus, Michaela ;

Meinicke, Thomas ;

Steubl, Dominik ;

Wanner, Christoph ;

Zinman, Bernard .

DIABETES OBESITY & METABOLISM, 2022, 24 (01) :135-141

[38] Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial [J].

Verma, Subodh ;

Leiter, Lawrence A. ;

Zinman, Bernard ;

Sharma, Abhinav ;

Mattheus, Michaela ;

Fitchett, David ;

George, Jyothis ;

Ofstad, Anne Pernille ;

Kosiborod, Mikhail N. ;

Wanner, Christoph ;

Inzucchi, Silvio E. .

ESC HEART FAILURE, 2021, 8 (04) :2603-2607

[39] Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial [J].

Fitchett, David ;

Inzucchi, Silvio E. ;

Zinman, Bernard ;

Wanner, Christoph ;

Schumacher, Martin ;

Schmoor, Claudia ;

Ohneberg, Kristin ;

Ofstad, Anne Pernille ;

Salsali, Afshin ;

George, Jyothis T. ;

Hantel, Stefan ;

Bluhmki, Erich ;

Lachin, John M. ;

Zannad, Faiez .

ESC HEART FAILURE, 2022, 8 (06) :4517-4527

[40] DECLARE-TIMI 58 TRIAL IN THE CONTEXT OF EMPA-REG OUTCOME AND CANVAS [J].

Shestakova, Marina, V .

DIABETES MELLITUS, 2019, 22 (06) :592-601

← 1 2 3 4 5 →